ArticleTranslational pediatrics2021
Safety of azithromycin in pediatric infectious diseases: a clinical systematic review and meta-analysis.
Article in Translational pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Safety and Efficacy of Oral Azithromycin for Gastrointestinal Dysmotility in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Gastrointestinal safety of oral erythromycin, clarithromycin, and azithromycin in pediatric patients: a FAERS pharmacovigilance study.Pediatric research · 2026Article
- Efficacy and Safety of Combined Treatment with Traditional Herbal Medicine and Western Medicine for Children with Pertussis-like Syndrome: Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2025Review
- Gallic acid synergistically enhances the antibacterial activity of azithromycin in MRSA.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Azithromycin Prevents Subglottic Stenosis in Mice.The Laryngoscope · 2025Article
- Article
- Is the safety of azithromycin superior to other antibiotics in the treatment of infectious diseases in children?Translational pediatrics · 2022Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAzithromycin is a second-generation macrolide antibiotic which can be used in the treatment of diseases caused by sensitive bacterial infections. This article aimed to investigate the safety of azithromycin in the treatment of infectious diseases in children by meta-analysis.
methodsPubMed, Embase, and Cochrane were selected as the search database platforms. Randomized controlled trials (RCTs) published after 2010 were searched using the following keywords: "azithromycin", "children", "adverse event", "intravenous event", and "oral". Included studies were all clinical trials of azithromycin in the treatment of pediatric diseases. After inclusion/exclusion criteria screening and bias risk assessment, data were extracted from the included studies. RevMan 5.3.5 software was used for statistical analysis to obtain both forest and funnel plots.
resultsA total of nine articles involving 3,597 pediatric patients were included in this study. The results of meta-analysis showed that the nine articles exhibited statistical heterogeneity (I DISCUSSION: Compared with other antibiotics, the clinical safety of azithromycin is relatively good, but care should be taken when the dosage is high in treating some disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.